Compare AKBA & LMNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | LMNR |
|---|---|---|
| Founded | 2007 | 1893 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 235.0M |
| IPO Year | 2014 | 2005 |
| Metric | AKBA | LMNR |
|---|---|---|
| Price | $1.23 | $13.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.67 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 4.1M | 74.5K |
| Earning Date | 05-07-2026 | 06-08-2026 |
| Dividend Yield | N/A | ★ 2.37% |
| EPS Growth | ★ 93.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $159,723,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $11.67 |
| 52 Week High | $3.81 | $16.62 |
| Indicator | AKBA | LMNR |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 46.20 |
| Support Level | $1.16 | $12.54 |
| Resistance Level | $1.52 | $13.65 |
| Average True Range (ATR) | 0.07 | 0.39 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 7.59 | 7.51 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.